CBO's recent score tallied temporary PAMA delay as a cost rather than a savings, potentially making future delays less likely but possibly raising the chances of permanent reform.

The digital immunoassay platform is designed to detect and quantify proteins at the single-molecule level in blood, serum, or plasm. The platform includes the HD-X Simoa Immunoassay Analyzer, which ...

The German startup is developing ultrasensitive lateral flow diagnostic tests that incorporate DNA origami signal amplification.

The test could potentially deliver noninvasive results in less than one minute through analysis of exhaled volatile organic compounds.

Uniogen's progress toward clinical commercialization aligns with larger internal goals of bringing cancer diagnostics to market, with a specific focus on women's health.

The test helps diagnose infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis.

The medical center will use PathAI's AISight Dx image management system to evaluate algorithms for a variety of applications.

The test, which will use Iso-PAS technology, will be developed by Nipro of Japan in collaboration with other companies, institutes, and nonprofit organizations.

The company is developing a noninvasive urine-based test for sexually transmitted infections including chlamydia and gonorrhea.

Hims & Hers obtains YourBio's microsampling tech, which the firm said will speed its efforts to improve blood collection, including outside traditional clinical settings.

The deal includes an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones.

NEW YORK – After rising 9 percent in October, the 360Dx Top 30 continued its upward momentum last month, rising an additional 9 percent in November. The 360Dx Top 30 outpaced the broader markets as ...